Saturday, 11 February 2017

Global Urological Cancer Therapeutics Drugs Sales Market Research Forecasts 2017

Global Urological Cancer Therapeutics Drugs Sales Market Report 2017 is a new market research publication announced by Reportstack. This report studies sales (consumption) of Urological Cancer Therapeutics Drugs in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering 
Novartis 
Pfizer 
Johnson & Johnson 
AstraZeneca 
Astellas 
Bristol-Myers Squibb 
Abbott Laboratories 
Celgene Corporation 
Dendreon Corporation 
Ferring Pharmaceuticals 
GlaxoSmithKline plc 
Indevus Pharmaceuticals Inc 
Ipsen 
Roche Healthcare 
Sanofi S.A.
Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Urological Cancer Therapeutics Drugs in these regions, from 2011 to 2021 (forecast), like 
United States 
China 
Europe 
Japan 
Southeast Asia 
India 
Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into 
Xofigo (radium Ra 223 dichloride) 
Jevtana (cabazitaxel) 
Inlyta (axitinib) 
Votrient (pazopanib hydrochloride) 
Sutent (sunitinib malate) 
Zytiga (abiraterone acetate) 
Xtandi (enzalutamide) 
Opdivo (nivolumab) 
Provenge (sipuleucel-T) 
Split by applications, this report focuses on sales, market share and growth rate of Urological Cancer Therapeutics Drugs in each application, can be divided into 
Hospital 
Medical Research Laboratory 
Others
Snapshot of TOC with Companies Mentioned
9 Global Urological Cancer Therapeutics Drugs Manufacturers Analysis 
9.1 Novartis 
9.1.1 Company Basic Information, Manufacturing Base and Competitors 
9.1.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification 
9.1.2.1 Xofigo (radium Ra 223 dichloride) 
9.1.2.2 Jevtana (cabazitaxel) 
9.1.3 Novartis Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017) 
9.1.4 Main Business/Business Overview 
9.2 Pfizer 
9.2.1 Company Basic Information, Manufacturing Base and Competitors 
9.2.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification 
9.2.2.1 Xofigo (radium Ra 223 dichloride) 
9.2.2.2 Jevtana (cabazitaxel) 
9.2.3 Pfizer Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017) 
9.2.4 Main Business/Business Overview 
9.3 Johnson & Johnson 
9.3.1 Company Basic Information, Manufacturing Base and Competitors 
9.3.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification 
9.3.2.1 Xofigo (radium Ra 223 dichloride) 
9.3.2.2 Jevtana (cabazitaxel) 
9.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017) 
9.3.4 Main Business/Business Overview 
9.4 AstraZeneca 
9.4.1 Company Basic Information, Manufacturing Base and Competitors 
9.4.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification 
9.4.2.1 Xofigo (radium Ra 223 dichloride) 
9.4.2.2 Jevtana (cabazitaxel) 
9.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017) 
9.4.4 Main Business/Business Overview 
9.5 Astellas 
9.5.1 Company Basic Information, Manufacturing Base and Competitors 
9.5.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification 
9.5.2.1 Xofigo (radium Ra 223 dichloride) 
9.5.2.2 Jevtana (cabazitaxel) 
9.5.3 Astellas Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017) 
9.5.4 Main Business/Business Overview 
9.6 Bristol-Myers Squibb 
9.6.1 Company Basic Information, Manufacturing Base and Competitors 
9.6.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification 
9.6.2.1 Xofigo (radium Ra 223 dichloride) 
9.6.2.2 Jevtana (cabazitaxel) 
9.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.6.4 Main Business/Business Overview 
9.7 Abbott Laboratories 
9.7.1 Company Basic Information, Manufacturing Base and Competitors 
9.7.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification 
9.7.2.1 Xofigo (radium Ra 223 dichloride) 
9.7.2.2 Jevtana (cabazitaxel) 
9.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017) 
9.7.4 Main Business/Business Overview 
9.8 Celgene Corporation 
9.8.1 Company Basic Information, Manufacturing Base and Competitors 
9.8.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification 
9.8.2.1 Xofigo (radium Ra 223 dichloride) 
9.8.2.2 Jevtana (cabazitaxel) 
9.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.8.4 Main Business/Business Overview 
9.9 Dendreon Corporation 
9.9.1 Company Basic Information, Manufacturing Base and Competitors 
9.9.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification 
9.9.2.1 Xofigo (radium Ra 223 dichloride) 
9.9.2.2 Jevtana (cabazitaxel) 
9.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017) 
9.9.4 Main Business/Business Overview 
9.10 Ferring Pharmaceuticals 
9.10.1 Company Basic Information, Manufacturing Base and Competitors 
9.10.2 Urological Cancer Therapeutics Drugs Product Type, Application and Specification 
9.10.2.1 Xofigo (radium Ra 223 dichloride) 
9.10.2.2 Jevtana (cabazitaxel) 
9.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2012-2017) 
9.10.4 Main Business/Business Overview 
9.11 GlaxoSmithKline plc 
9.12 Indevus Pharmaceuticals Inc 
9.13 Ipsen 
9.14 Roche Healthcare 
9.15 Sanofi S.A.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)